A sustainable future for HIV prevention The Lancet HIV ++ +... +...

A sustainable future for HIV prevention The Lancet HIV https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00360-1/fulltext?dgcid=raven_jbs_etoc_email Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial Anushka Naidoo, PhDa,b anushka.naidoo@caprisa.org ∙ Kogieleum Naidoo, PhDa,b ∙ Marothi P Letsoalo, MSca ∙ Roeland E Wasmann, PhDc ∙ Gillian Dorse, MBChBa ∙ Rubeshan Perumal, PhDa,b ∙ et al. https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00200-0/abstract?dgcid=raven_jbs_etoc_feature_lanhiv Sustainable HIV prevention in Africa https://www.thelancet.com/series-do/sustainable-hiv-prevention-africa?dgcid=raven_jbs_etoc_feature_hivprevention25_lanhiv Jan 2026 Volume 13Number 1e1-e70 https://www.thelancet.com/journals/lanhiv/issue/vol13no1/PIIS2352-3018(25)X0013-8